Intra-Cellular Therapies Культура компании

Dr. Kimberly E. Vanover, Ph.D. has been Senior Vice President of Clinical Development at Intra-Cellular Therapies, Inc. since November 2015. Dr. Vanover served as the Vice President of Clinical Development at Intra-Cellular Therapies, Inc. (also known as ITI) since August 2013. Dr. Vanover joined Intra-Cellular Therapies in 2007. She has spent over 15 years on the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases. She held positions at Lederle Laboratories, the University of California San Diego, CoCensys and ACADIA Pharmaceuticals. In these positions, she participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy and drug abuse. She holds B.A. in Psychology from University of Missouri. She completed her Ph.D. in the field of Biopsychology from the University of Chicago.

Dr. Robert E. Davis, Ph.D. has been Chief Scientific Officer and Senior Vice President at Intra-Cellular Therapies, Inc. since November 2015. Dr. Davis served as President and Chief Executive Officer of 3-D Pharmaceutical Consultants, providing consulting services from December 2005 to November 2015. From December 2000 to November 2005, he served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. He served as Executive Vice President of Drug Discovery and Development at Acadia Pharmaceuticals Inc. since February 2001. Dr. Davis was a founding member of Acadia Pharmaceuticals Inc.'s Scientific Advisory Board and served as a Consultant to Acadia Pharmaceuticals Inc. from November 2000 until becoming an employee. From January 1994 to October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company, ultimately serving as its President, Chief Executive Officer and Chief Scientific Officer. During his tenure, MitoKor grew from five to 110 employees. Earlier in his career, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert Company including Director of Neurodegenerative Diseases. In the latter capacity, Dr. Davis chaired or participated in research and development teams that advanced ten new chemical entities into clinical development. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer's disease, Neurontin, the first drug approved for treating neuropathic pain and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease. Dr. Davis serves on the editorial boards of a number of journals including Neurobiology of Aging, Current Opinions in Investigational drugs and Emerging Therapeutics. Dr. Davis completed his postdoctoral work at the University of California, Los Angeles. He received his B.S., M.S. and Ph.D. in Psychobiology at the University of Illinois, Chicago.

Mr. Lawrence J. Hineline, CPA, has been Chief Financial Officer, Vice President of Finance and Treasurer at Intra-Cellular Therapies, Inc. since June 2002 & August 2013 respectively. Mr. Hineline served as Secretary of Intra-Cellular Therapies, Inc. since August 2013 until September 2014. He served as a Vice President and Chief Financial Officer of Functional Genetics, Inc. from 2000 to 2003. He served as a North American Vaccine and its predecessor companies as Vice President of Finance from 1993 to 2000 and its Corporate Controller from 1989 to 1993 and also serves as its Principal Financial and Accounting Officer. He oversaw the growth of the Accounting function and its systems for this company that emerged as a start-up and was later acquired by Baxter Health Care. Prior to 1989, he held the position of Controller for several businesses and from 1981 to 1984, he worked in the Audit Department of Deloitte & Touche serving clients in a variety of industries. He is a licensed CPA in the State of Maryland. He received Bachelor's Degree from University of Maryland.

Mr. Michael I. Halstead has been Senior Vice President and General Counsel at Intra-Cellular Therapies, Inc., since July 2014 and its Secretary since September 2014. Mr. Halstead also serves as Corporate Compliance Officer of Intra-Cellular Therapies, Inc. He served as Senior Vice President of Corporate Development at Warner Chilcott plc from June 2011. He was responsible for business development as well as human resources, aviation and certain Puerto Rican business operations. He joined Warner Chilcott in May 2005 and held positions of increasing responsibility including most recently, Vice President, Human Resources. Prior to joining Warner Chilcott, Mr. Halstead was an associate with the law firm Davis Polk & Wardwell LLP. Mr. Halstead received his bachelor's degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

Daniel Utzinger serves as the VP & CIO for Intra-Cellular Therapies. Daniel started at Intra-Cellular Therapies in March of 2018. Daniel is based in the Greater New York City Area.

Susan Kozauer serves as the VP Clinical Development for Intra-Cellular Therapies. Susan started at Intra-Cellular Therapies in November of 2017. Susan is based in the Washington D.C. Metro Area.

Andrew Satlin serves as the Chief Medical Officer for Intra-Cellular Therapies. Andrew started at Intra-Cellular Therapies in November of 2017. Andrew is based in the Greater New York City Area.

Mark Neumann serves as the Executive Vice President, Chief Commercial Officer of Intra-Cellular Therapies. Mark currently resides in the Greater New York City Area.